Article

Traitement médicamenteux Glucosamine and chondroitin are members of a group of dietary supplements often
termed "complementary agents," "disease-modifying agents," or "disease-modifying
osteoarthritis drugs" (DMOADs). They are among the best-selling dietary
supplements in the United States. DMOADs are thought to act by affecting
cytokine-mediated pathways regulating inflammation, cartilage degradation, and
immune responses. Given the results of recent studies, investigators have begun
to question whether the popular combination of glucosamine and chondroitin
alleviates disease progression or pain in people with mild to moderate knee
osteoarthritis. Reasons proposed for the lack of benefit include incorrect
dosing, suboptimal compound manufacture, and a lack of complete understanding of
when and how to apply the compounds. In addition, adjuvant medications also could
augment the therapeutic potential of these agents. Although these agents are
considered safe, some uncommon and minor adverse effects have been reported,
including epigastric pain or tenderness (3.5%), heartburn (2.7%), diarrhea
(2.5%), and nausea (1%). In conclusion, although some questions have arisen about
whether DMOADs are as effective as has been claimed, a trial should be considered
in in selected patients with sustained refractory cases of osteoarthritis.
CI - Copyright (c) 2012 American Academy of Physical Medicine and Rehabilitation.
Published by Elsevier Inc. All rights reserved.

Langue : ANGLAIS